Strate­gic In­dus­try

Be­larus’ phar­ma­ceu­ti­cal in­dus­try is gath­er­ing mo­men­tum

Economy of Belarus - - INNOVATIONS - Olga BELYAVSKAYA, Econ­omy of Be­larus Mag­a­zine

Mr Usanov, can the phar­ma­ceu­ti­cal in­dus­try be­come one of the ma­jor rev­enue­earn­ers in our coun­try?

Like many other coun­tries, Be­larus at­taches ut­most im­por­tance to this in­dus­try. Phar­ma­ceu­tics and biotech­nolo­gies have re­cently be­come the fastest grow­ing in­dus­tries in the de­vel­oped and de­vel­op­ing coun­tries demon­strat­ing a 10% growth per year. In 2010 alone, the to­tal sales of phar­ma­ceu­ti­cal prod­ucts on the ma­jor global phar­ma­ceu­ti­cal mar­kets made $656.5 bil­lion.

Be­larus’ phar­ma­ceu­ti­cal in­dus­try is on the thresh­old of re­mark­able trans­for­ma­tions. Five years from now, it will grow into one of the most in­no­va­tion-in­ten­sive do­mes­tic in­dus­tries. The Be­laru­sian phar­ma­ceu­ti­cal in­dus­try will, in fact, get a new face which will be well-rec­og­nized not only in the coun­try, but through­out the world. Be­larus is go­ing to sell more do­mes­tic drugs and vi­ta­mins, which qual­ity will ri­val im­ported ones. Di­rec­tor Gen­eral of the Chem­i­cal Syn­the­sis and Biotech­nolo­gies Re­search Cen­ter, chief of the In­sti­tute of Bioor­ganic Chem­istry, mem­ber of the National Academy of Sciences of Be­larus, Pro­fes­sor Sergei USANOV tells the Econ­omy of Be­larus Mag­a­zine about the new de­vel­op­ment strat­egy and new im­age of the in­dus­try, new tech­nolo­gies and in­vest­ment projects.

The fig­ure is not so im­pres­sive in Be­larus. For ex­am­ple, in 2010 the do­mes­tic mar­ket was es­ti­mated at $676.5 mil­lion in sell­ing prices, up by 9.9% in money terms and up by 1.2% in phys­i­cal terms. In Jan­uary-au­gust 2011, the Be­laru­sian phar­ma­ceu­ti­cal mar­ket ex­panded by 5.6% in money terms and by 6.8% in phys­i­cal terms. Over 6,000 drugs and phar­ma­ceu­ti­cal sub­stances have been reg­is­tered in Be­larus, of which 950 names are pro­duced by do­mes­tic com­pa­nies.

This is nat­u­rally not enough to ad­vance to the lead­ing po­si­tions. At present, Be­larus-made phar­ma­ceu­ti­cal sub­stances ac­count for 26% of the drug pro­duc­tion tech­nolo­gies, while the im­ported sub­stances are worth dozens of mil­lions of dol­lars. The coun­try still heav­ily re­lies on phar­ma­ceu­ti­cal imports.

This is­sue is to be ad­dressed by the phar­ma­ceu­tics and biotech­nolo­gies de­vel­op­ment con­cept for 20112015 and for the pe­riod un­til 2020. Its ma­jor ob­jec­tive is to re­duce the re­liance on drug imports by in­creas­ing the share of do­mes­tic drugs in to­tal con­sump­tion up to 50% in money terms.

In line with the in­struc­tions of the head of state, by 2015 Be­laru­sian com­pa­nies should in­crease the phar­ma­ceu­ti­cal pro­duc­tion three times com­pared with 2010. The ex­port of medicines should rise by not less than 3.7-4 times, in­clud­ing by means of GMP cer­ti­fi­ca­tion of the ex­ist­ing pro­duc­tion.

In line with the govern­ment pro­gram “Im­port sub­sti­tut­ing phar­ma­ceu­ti­cal prod­ucts”, Be­larus is set to es­tab­lish 12 new pro­duc­tion fa­cil­i­ties to make im­port sub­sti­tut­ing phar­ma­ceu­ti­cal sub­stances and fin­ished phar­ma­ceu­ti­cal and di­ag­nos­tic prod­ucts, in­clud­ing 32 phar­ma­ceu­ti­cal sub­stances and 110 drugs, in­clud­ing 53 orig­i­nal ones. What re­forms will be im­ple­mented in the do­mes­tic phar­ma­ceu­ti­cal in­dus­try?

Re­forms are al­ready un­der­way. The head of state passed De­cree

The share of Be­larus-made medicines should reach 50% on the do­mes­tic mar­ket

by 2015

Newspapers in English

Newspapers from Belarus

© PressReader. All rights reserved.